STOCKHOLM, Aug. 31, 2022 /PRNewswire/ -- Hemcheck Sweden AB has today received a first follow-up order from its Greek distributor Antisel. The order is of lower economic value but shows that Antisel is active in the market and that Greek customers are in demand of Hemcheck's products.
"We view this order as very positive, since the Greek market previously has been affected by covid restrictions for a long time, which now are significantly reduced. We therefore hope that this is the start of several recurring orders," says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)Joen Averstad, CEOTel: +46 76 108 8191Email: joen.averstad@hemcheck.com
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hemcheck/r/hemcheck-receives-follow-up-order-from-its-greek-distributor,c3623848
The following files are available for download: